(Billable Hours is Reuters' weekly report on lawyers and money. Please send tips or suggestions to ...

Medicare no longer covers Wegovy specifically for weight loss purposes, though coverage may still be available when ...

Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions ...

Retail investor sentiment around Hims & Hers Health remained negative over the weekend after the telehealth firm confirmed it ...

A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...

Telehealth platform Hims & Hers said on Friday it will cut 68 employees, or about 4% of its workforce, as it adjusts to a U.S ...

A new study has compared Wegovy and Zepbound head-to-head in their ability to treat obesity. People taking Eli Lilly’s ...

Dozens of Ozempic, Mounjaro and Wegovy users are reporting drug-induced hepatitis, prompting medical experts to call for ...

Novo Nordisk has filed a lawsuit in Delhi High Court. The suit aims to stop Dr Reddy's Laboratories and OneSource from ...

HIMS showcases outstanding financial strength. With just $63 million in debt against a market value of $13 billion, the ...

In an effort to promote the use of genuine products, Novo Nordisk is offering a one-time first-month offer for Wegovy at $199 ...